Literature DB >> 30327358

Prolonged Prothrombotic Effects of Antecedent Hypoglycemia in Individuals With Type 2 Diabetes.

Elaine Chow1,2, Ahmed Iqbal1,2, Emma Walkinshaw2,3, Fladia Phoenix4, Ian A Macdonald5, Robert F Storey1,3, Ramzi Ajjan4, Simon R Heller6,3.   

Abstract

OBJECTIVE: Hypoglycemia has been linked to persistent increases in cardiovascular (CV) mortality in type 2 diabetes after the event. Our aim was to examine acute and downstream effects of hypoglycemia on markers of thrombosis risk and inflammation in type 2 diabetes. RESEARCH DESIGN AND METHODS: Twelve individuals with type 2 diabetes with no history of CV disease and 11 age- and BMI-matched volunteers without diabetes underwent paired hyperinsulinemic-euglycemic (glucose 6 mmol/L for two 60-min periods) and hypoglycemic (glucose 2.5 mmol/L for two 60-min periods) clamps on separate occasions on day 0. Fibrin clot properties, platelet reactivity, and inflammatory markers were measured at baseline, end of and after recovery from the initial clamp, day 1, and day 7 using validated assays and electron microscopy.
RESULTS: Euglycemic hyperinsulinemia reduced platelet reactivity, decreased fibrin clot density, and improved fibrinolytic efficiency in both groups. Platelet reactivity and aggregation increased during acute hypoglycemia in both groups, resolving at recovery. In type 2 diabetes, clot lysis times and clot maximum absorbance increased up to day 7 (P = 0.002 and 0.001 vs. euglycemia, respectively), but clots from control subjects without diabetes showed limited changes. Fibrin network density increased Δ 1.15 ± 0.28 fibers/μm2 at day 7 after the hypoglycemic clamp (P < 0.01 for glycemic arm), whereas fibrinogen and complement C3 increased after hypoglycemia up to day 7 in type 2 diabetes only.
CONCLUSIONS: Antecedent hypoglycemia has acute and persistent prothrombotic effects, lasting at least 7 days, that were enhanced in individuals with type 2 diabetes. These findings identify mechanisms by which hypoglycemia might increase short- and medium-term risk of CV mortality.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30327358     DOI: 10.2337/dc18-0050

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  15 in total

Review 1.  The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it.

Authors:  Alicia Jenkins; Andrzej Januszewski; David O'Neal
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-02-13

2.  Identification of Reactive Hypoglycemia with Different Basic BMI and Its Causes by Prolonged Oral Glucose Tolerance Test.

Authors:  Xue Lv; Kun Fang; Wenqing Hao; Yuxin Han; Nailong Yang; Qing Yu
Journal:  Diabetes Metab Syndr Obes       Date:  2020-12-02       Impact factor: 3.168

3.  Flash Presentations.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2022-06       Impact factor: 6.960

4.  Hypoglycaemia leads to a delayed increase in platelet and coagulation activation markers in people with type 2 diabetes treated with metformin only: Results from a stepwise hypoglycaemic clamp study.

Authors:  Felix Aberer; Peter N Pferschy; Norbert J Tripolt; Caren Sourij; Anna M Obermayer; Florian Prüller; Eva Novak; Philipp Reitbauer; Harald Kojzar; Barbara Prietl; Selina Kofler; Martina Brunner; Eva Svehlikova; Tatjana Stojakovic; Hubert Scharnagl; Abderrahim Oulhaj; Faisal Aziz; Regina Riedl; Harald Sourij
Journal:  Diabetes Obes Metab       Date:  2019-11-03       Impact factor: 6.577

5.  The effect of hypoglycaemia during hospital admission on health-related outcomes for people with diabetes: a systematic review and meta-analysis.

Authors:  A Lake; A Arthur; C Byrne; K Davenport; J M Yamamoto; H R Murphy
Journal:  Diabet Med       Date:  2019-09-29       Impact factor: 4.359

6.  Reduction in cardiovascular mortality following severe hypoglycemia in individuals with type 2 diabetes: the role of a pragmatic and structured intervention : Structured intervention for community hypoglycemia.

Authors:  Sam M Pearson; Beverley Whittam; Kavita Kulavarasalingam; Amelia Mitchell-Gears; Cathyrn James; Ramzi A Ajjan
Journal:  Cardiovasc Diabetol       Date:  2021-01-12       Impact factor: 9.951

7.  Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients.

Authors:  James Ling; Emily W M Poon; Aimin Yang; Theresa Yeung; Kitman Loo; Risa Ozaki; Ronald C W Ma; Andrea O Y Luk; Alice P S Kong; Juliana C N Chan; Elaine Chow
Journal:  Diabetes Ther       Date:  2021-03-18       Impact factor: 2.945

Review 8.  Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis.

Authors:  Xiaoling Li; Nina C Weber; Danny M Cohn; Markus W Hollmann; J Hans DeVries; Jeroen Hermanides; Benedikt Preckel
Journal:  J Clin Med       Date:  2021-05-29       Impact factor: 4.241

Review 9.  A Bittersweet Response to Infection in Diabetes; Targeting Neutrophils to Modify Inflammation and Improve Host Immunity.

Authors:  Rebecca Dowey; Ahmed Iqbal; Simon R Heller; Ian Sabroe; Lynne R Prince
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

10.  Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study.

Authors:  Wael Sumaya; Lars Wallentin; Stefan K James; Agneta Siegbahn; Katja Gabrysch; Anders Himmelmann; Ramzi A Ajjan; Robert F Storey
Journal:  Thromb Haemost       Date:  2020-01-23       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.